Table 1 Summary of clinicopathological characteristics and peptide-specific CTL induction from the peripheral blood mononuclear cells of prostate cancer patients
Case no. | Age (years old) | PSA (ng/ml) | Gleason score | Pathologic stage | AMACR expression | CTL induction | Peptide specificity |
|---|---|---|---|---|---|---|---|
1 | 60 | 6.7 | 4+3 | T2aN0M0 | + | + | AMACR2 |
2 | 73 | 6.0 | 3+3 | T2aN0M0 | + | + | AMACR2 |
3 | 65 | 11.6 | 4+3 | T2bN0M0 | + | + | AMACR2 |
4 | 64 | 15.6 | 3+4 | T3aN0M0 | + | + | AMACR1 |
5 | 67 | 18.4 | 4+5 | T3aN0M0 | + | + | AMACR1,2,3 |
6 | 67 | 14.4 | 4+3 | T2bN0M0 | + | + | AMACR1,2,3 |
7 | 71 | 10.9 | 3+5 | T3bN0M0 | + | - | - |
8 | 71 | 4.6 | 3+4 | T2aN0M0 | + | - | - |
9 | 72 | 5.7 | 3+4 | T2aN0M0 | + | - | - |
10 | 67 | 8.0 | 4+4 | T2aN0M0 | + | - | - |
11 | 67 | 4.3 | 3+3 | T2bN0M0 | + | - | - |
12 | 61 | 11.5 | 3+4 | T2aN0M0 | - | - | - |
13 | 61 | 10.1 | 4+3 | T2bN0M0 | - | - | - |
14 | 61 | 10.4 | 3+4 | T2aN0M0 | - | - | - |
15 | 60 | 6.6 | 3+4 | T2aN0M0 | - | - | - |